Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Inclusion Criteria: * Must have a Pinhole visual acuity (VA) equal to or better than 20/40 in both eyes. * Must be in good ocular health Exclusion Criteria: * Subjects who have known hypersensitivity or contraindication to the study drug or its components. * Subjects who currently require or are expected to require treatment with any medication listed as a disallowed medication per the Disallowed Therapy section of the protocol. * Any topical ophthalmic medication, including tear substitutes that cannot be discontinued during the study. * Subjects who are monocular (fellow eye is absent or fellow eye's Pinhole VA is worse than 20/200). * Subjects with a history of ocular surgery, or who anticipate ocular surgery in either eye within the study period. * Presence of significant ocular or systemic disease that the Investigator determines could interfere with the study.